Pacific Biosciences of California Inc. (PACB) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, PACB scores 44 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

• Fundamental Cash Engine: 9 / 20. Per the RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -12.64%. For a prospective investor, this means the business is currently consuming cash relative to its market value rather than generating it, which removes the cash-flow support that typically anchors valuation.
• Whale 13F Flow: 16 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. This is the strongest pillar and indicates some institutional interest, which is a potential upside driver, though the source data does not itemize the holders behind it.
• Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score is the weakest signal in the rating and suggests insider activity is not supportive of the stock.
• Macro Regime Fit: 8 / 20. Per the RQD rating, this reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock moves in line with the broad market, so it offers no defensive cushion in a downturn.
• Forensic Balance Sheet: 8 / 20. Per the RQD rating, this reflects an Altman Z of 2.5, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5. The weak Piotroski reading points to deteriorating financial quality, though leverage itself is moderate.

Taken together, the valuation tradeoff is that the stock trades at a $901.4M market capitalization against sustained operating losses, so upside depends on a turnaround in cash generation that the current data does not yet show. The main upside driver is the institutional positioning pillar; the main downside risk is the combination of negative FCF yield and weak forensic scores.

Pacific Biosciences of California Inc. (PACB) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Laboratory Analytical Instruments, per the company profile. The source data does not detail its product lines, customer base, or revenue model beyond reported revenue. The profile identifies its market capitalization as $0.9B. Revenue reported in the SEC financials was $160.0M for FY 2025.

Per the SEC financials, the company reported operating losses in each period shown, with operating income of $-553.9M in FY 2025. Per the market data, operating margin and net margin are both -60% and gross margin is 28.6%. Per the Roarable RQD rating, ROIC is -35%, and the forensic inputs are an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5. Cash rose from $55.4M to $63.7M between FY 2024 and FY 2025 while free cash flow remained negative in every period.

Per the recent news feed, the catalysts consist of market-wire coverage from Yahoo Finance, CNN, StockInvest.us, TradingView, and Investing.com, each tagged with a YELLOW signal. The headlines describe the stock declining more than the market, a Pacific Biosciences CFO reporting a $2.05m stock sale, and PacBio shares trading up on a given day. Per the news feed, these items are general market coverage rather than company-specific fundamental announcements, and the source data does not describe the underlying events.

Risk watch items include the CFO stock sale, which is an insider-selling signal, and the recent 52-week decline toward the low end of the range. Per the butterfly supply-chain graph, there are no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or cross-sector correlations. Investors should note that the absence of mapped links means the sector sensitivity referenced in the RQD Macro Regime pillar is not traced to specific counterparties in this dataset.

• What are the company's revenue drivers and customer concentration, given that the source data provides only aggregate reported revenue?
• What is the path to positive free cash flow, given negative FCF in all three reported periods?
• What is the composition of the institutional holders behind the 16/20 whale flow score, since the holders section is empty?
• What do the CFO stock sale and the insider flow score imply about management's view of the business?
• What drives the gap between the $63.7M cash balance and the reported debt, which is not disclosed in the source data?